Literature DB >> 23727436

BDNF in fragile X syndrome.

Maija L Castrén1, Eero Castrén.   

Abstract

Fragile X syndrome (FXS) is a monogenic disorder that is caused by the absence of FMR1 protein (FMRP). FXS serves as an excellent model disorder for studies investigating disturbed molecular mechanisms and synapse function underlying cognitive impairment, autism, and behavioral disturbance. Abnormalities in dendritic spines and synaptic transmission in the brain of FXS individuals and mouse models for FXS indicate perturbations in the development, maintenance, and plasticity of neuronal network connectivity. However, numerous alterations are found during the early development in FXS, including abnormal differentiation of neural progenitors and impaired migration of newly born neurons. Several aspects of FMRP function are modulated by brain-derived neurotrophic factor (BDNF) signaling. Here, we review the evidence of the role for BDNF in the developing and adult FXS brain. This article is part of the Special Issue entitled 'BDNF Regulation of Synaptic Structure, Function, and Plasticity'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-methyl-6-(phenylethynyl)pyridine hydrochloride; ADHD; Autism; BDNF; Brain-derived neurotrophic factor; CYFIP1; Circuit function; Differentiation; FMR1 gene; FMR1 protein; FMRP; FMRP-interacting protein; FXS; FXTAS; Fmr1 KO; Fmr1 gene; Fragile X syndrome; GABA; IP; LTD; LTP; MPEP; Mental retardation; N-methyl-d-aspartate receptor; NMDA; NPC; Neural progenitors; RNA interference; RNAi; TrkB receptor; aNPCs; adult neural progenitor cells; attention deficit and/or hyperactive disorder; fragile X mental retardation 1 gene; fragile X mental retardation 1 knockout; gamma-aminobutyric acid; gp1; group 1; intermediate progenitor; long-term depression; long-term potentiation; mGluR; metabotropic glutamate receptor; neural progenitor cells; tremor/ataxia syndrome; tropomyosin-related kinase B receptor

Mesh:

Substances:

Year:  2013        PMID: 23727436     DOI: 10.1016/j.neuropharm.2013.05.018

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  22 in total

1.  Molecular mechanisms regulating impaired neurogenesis of fragile X syndrome human embryonic stem cells.

Authors:  Michael Telias; Yoav Mayshar; Ami Amit; Dalit Ben-Yosef
Journal:  Stem Cells Dev       Date:  2015-10-15       Impact factor: 3.272

2.  Delayed Maturation of Fast-Spiking Interneurons Is Rectified by Activation of the TrkB Receptor in the Mouse Model of Fragile X Syndrome.

Authors:  Toshihiro Nomura; Timothy F Musial; John J Marshall; Yiwen Zhu; Christine L Remmers; Jian Xu; Daniel A Nicholson; Anis Contractor
Journal:  J Neurosci       Date:  2017-10-16       Impact factor: 6.167

Review 3.  Serotonin dysregulation in Fragile X Syndrome: implications for treatment.

Authors:  Alicia C Hanson; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2014-11

Review 4.  Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links.

Authors:  S W Hulbert; Y-H Jiang
Journal:  Neuroscience       Date:  2015-12-28       Impact factor: 3.590

Review 5.  RNA-binding proteins, neural development and the addictions.

Authors:  C D Bryant; N Yazdani
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

6.  Tissue plasminogen activator contributes to alterations of neuronal migration and activity-dependent responses in fragile X mice.

Authors:  V Swaroop Achuta; Veronika Rezov; Marko Uutela; Verna Louhivuori; Lauri Louhivuori; Maija L Castrén
Journal:  J Neurosci       Date:  2014-01-29       Impact factor: 6.167

7.  Acute pharmacological inhibition of matrix metalloproteinase-9 activity during development restores perineuronal net formation and normalizes auditory processing in Fmr1 KO mice.

Authors:  Patricia S Pirbhoy; Maham Rais; Jonathan W Lovelace; Walker Woodard; Khaleel A Razak; Devin K Binder; Iryna M Ethell
Journal:  J Neurochem       Date:  2020-06-08       Impact factor: 5.372

8.  BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1.

Authors:  Maja Genheden; Justin W Kenney; Harvey E Johnston; Antigoni Manousopoulou; Spiros D Garbis; Christopher G Proud
Journal:  J Neurosci       Date:  2015-01-21       Impact factor: 6.167

Review 9.  Characterizing autism spectrum disorders by key biochemical pathways.

Authors:  Megha Subramanian; Christina K Timmerman; Joshua L Schwartz; Daniel L Pham; Mollie K Meffert
Journal:  Front Neurosci       Date:  2015-09-24       Impact factor: 4.677

10.  FMRP Interacts with RARα in Synaptic Retinoic Acid Signaling and Homeostatic Synaptic Plasticity.

Authors:  Esther Park; Anthony G Lau; Kristin L Arendt; Lu Chen
Journal:  Int J Mol Sci       Date:  2021-06-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.